A Non-interventional Biomarker Study in Patients With Non-Small Cell Lung Cancer (NSCLC) of Adenocarcinoma Tumour Histology Eligible for Treatment With Vargatef® According to the Approved Label.

Trial Profile

A Non-interventional Biomarker Study in Patients With Non-Small Cell Lung Cancer (NSCLC) of Adenocarcinoma Tumour Histology Eligible for Treatment With Vargatef® According to the Approved Label.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Nintedanib (Primary)
  • Indications Adenocarcinoma; Non-small cell lung cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms LUME BioNIS
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 19 Sep 2017 Planned End Date changed from 15 Nov 2020 to 1 Nov 2021.
    • 19 Sep 2017 Planned primary completion date changed from 15 Apr 2020 to 1 Apr 2021.
    • 12 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top